[1]李盟,赵迪,杜燕青,等.参佛胃康治疗慢性萎缩性胃炎胃癌前病变作用机制研究[J].西部中医药,2024,37(09):30-34.[doi:10.12174/j.issn.2096-9600.2024.09.07]
 LI Meng,ZHAO Di,DU Yanqing,et al.Study on the Mechansim of Shenfo Weikang in the Treatment of Precancerous Lesions of Gastric Cancer: Chronic Atrophic Gastritis[J].Western Journal of Traditional Chinese Medicine,2024,37(09):30-34.[doi:10.12174/j.issn.2096-9600.2024.09.07]
点击复制

参佛胃康治疗慢性萎缩性胃炎胃癌前病变作用机制研究
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
37
期数:
2024年09期
页码:
30-34
栏目:
基础研究
出版日期:
2024-09-15

文章信息/Info

Title:
Study on the Mechansim of Shenfo Weikang in the Treatment of Precancerous Lesions of Gastric Cancer: Chronic Atrophic Gastritis
作者:
李盟1, 赵迪1, 杜燕青2, 李特3, 蔺焕萍1, 周小燕4
1.陕西中医药大学,陕西 咸阳 712046
2.湖州市中医院 浙江 湖州 313000
3.西安市第九医院,陕西 西安 710054
4.陕西中医药大学附属医院,陕西 咸阳 712000
Author(s):
LI Meng1, ZHAO Di1, DU Yanqing2, LI Te3, LIN Huanping1, ZHOU Xiaoyan4
1.Shaanxi University of Chinese Medicine, Xianyang 712046, China
2.Huzhou Hospital of Traditional Chinese Medicine, Huzhou 313000, China
3.Xi'an No. 9 Hospital, Xi'an 710054, China
4.Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang 712000, China
关键词:
萎缩性胃炎胃癌前病变磷脂酰肌醇3-激酶/蛋白激酶BB细胞淋巴瘤-2蛋白信号通路参佛胃康丽珠得乐
Keywords:
atrophic gastritisprecancerous lesions of gastric cancerPI3l/AktBcl-2 proteinsignaling pathwaycolloidal bismuth subcitrate capsules
分类号:
R256.39
DOI:
10.12174/j.issn.2096-9600.2024.09.07
文献标志码:
A
摘要:
目的探讨参佛胃康治疗慢性萎缩性胃炎胃癌前病变的作用机制。 方法利用Wistar大鼠制备胃癌前病变模型,空白组6只不造模,其余大鼠通过综合性N-甲基-N'-硝基-N-亚硝基胍(1-Methyl-3-nitro-1-nitrosoguanidine,MNNG)复合造模方法制备胃癌前病变模型,将建模成功的大鼠随机分为模型组、参佛胃康组、丽珠得乐组,空白组及模型组灌胃生理盐水,参佛胃康组及丽珠得乐组予相应剂量参佛胃康1.22 g/(kg·d)和丽珠得乐0.18 g/(kg·d),各组均干预4周。干预结束后,观察各组大鼠一般情况;苏木素-伊红(hematoxylin-eosin,HE)染色观察大鼠胃组织病理学变化情况;Western Blot法检测胃黏膜组织中磷脂酰肌醇3-激酶/蛋白激酶B(phosphatidylinositol 3-kinase/protein kinase B,PI3K/Akt)信号通路相关蛋白及B细胞淋巴瘤2(B cell lymphoma-2 protein,Bcl-2)蛋白表达水平。 结果参佛胃康组大鼠毛色、精神状况、体质量、食欲、大便等一般情况优于模型组。与模型组比较,丽珠得乐组大鼠胃黏膜腺体数量减少,排列欠规则,但炎性细胞浸润程度较模型组轻,部分区域可见充血、水肿以及淋巴细胞聚集;参佛胃康组大鼠胃黏膜上皮相对完整,细胞形态相对均匀,腺体数量较多,分布排列相对整齐且规则。与模型组比较,丽珠得乐组和参佛胃康组Bcl-2蛋白的相对表达降低,p-PI3K/PI3K、p-Akt/Akt比例均降低(P<0.05),参佛胃康组低于丽珠得乐组(P<0.05)。 结论参佛胃康能够改善慢性萎缩性胃炎胃癌前病变大鼠一般情况及其胃黏膜病理状态,其作用机制可能与参佛胃康调控PI3K/Akt信号通路,抑制PI3K、Akt、Bcl-2蛋白表达,影响细胞凋亡有关。
Abstract:
ObjectiveTo discuss the mechanism of Shenfo Weikang in the treatment of precancerous lesions of gastric cancer (PLGC) in chronic atrophic gastritis (CAG) patients. MethodsWistar rats were utilized to establish PLGC models, six rats in the blank group remained unhandled, other rats were prepared into PLGC models by MNNG, after successfully modeling, the rats were randomized into the model group, Shenfo Weikang group and colloidal bismuth subcitrate capsules group, the blank group and the model group accepted intragastric administra-tion of physiological saline, Shenfo Weikang group and colloidal bismuth subcitrate capsules group were given the corresponding dosages of Shenfo Weikang, 1.22 g/(kg·d), and colloidal bismuth subcitrate capsules, 0.18 g/(kg·d), all the groups were intervened for four weeks. By the end of intervention, to observe the general conditions of the rats in different groups; HE staining was used to observe pathological changes of the stomach in the rats; western blot (WB) was applied to detect the expressions of PI3l/Akt signaling pathway and Bcl-2 protein in gastric mucosa. ResultsThe general conditions including coat colour, mental state, body mass, appetite, defecation and others of Shenfo Weikang were superior to these of the model group. Compared with the model group, the number of glands in gastric mucosa decreased and arranged less regularly in colloidal bismuth subcitrate capsules group, but the degree of inflammatory cell infiltration was milder than that in the model group, and congestion, edema, and lymphocyte accumulation were observed in some areas; the gastric mucosal epithelium is relatively intact, with a relatively uniform cell morphology, a large number of glands, arranged in a relatively orderly and regular pattern. Compared with the model group,the relative expressions of Bcl-2 reduced in colloidal bismuth sublitrate capsules group, and shenfo weikang group.The ratios of p-PI3K/PI3K, p-Akt/Akt reduced in colloidal bismuth subcitrate capsules group and ShenfoWeikang group (P<0.05), Shenfo Weikang group was lower than colloidal bismuth subcitrate capsules group (P<0.05). ConclusionShenfo Weikang could improve PLGC rats' general conditions and their pathological state of gastric mucosa, and its mechanism might be related to that Shenfo Weikang could regulate PI3l/Akt signaling pathway, inhibit the expressions of PI3K, Akt and Bcl-2 protein and affect cellular apoptosis.

相似文献/References:

[1]樊斗霜.枳实消痞丸(汤)合丹参饮加减治疗慢性萎缩性胃炎32例[J].西部中医药,2013,26(02):72.
 FAN Doushuang.Modified ZhiShi XiaoPiWan(Prescription) and DanShenYin in Treating 32 Cases of Chronic Atrophic Gastritis[J].Western Journal of Traditional Chinese Medicine,2013,26(09):72.
[2]李朕,李琦,杨军用,等.十三味健胃饮与胃复春片治疗胃癌前病变疗效比较[J].西部中医药,2019,32(05):81.
 LI Zhen,LI Qi,YANG Junyong,et al.The Comparison of Clinical Effects of ShiSanWei JianWei Drink and WeiFuChun Tablets in the Treatment for Precancerous Lesion of Gastric Cancer[J].Western Journal of Traditional Chinese Medicine,2019,32(09):81.
[3]董刘佳,苗嘉萌,袁红霞.袁红霞教授从疏利三焦探讨胃癌前病变辨治思路[J].西部中医药,2021,34(07):58.[doi:10.12174/j.issn.2096-9600.2021.07.14]
 DONG Liujia,MIAO Jiameng,YUAN Hongxia.Professor Yuan Hongxia’s Thinking on Differentiating and Treating Precancerous Lesions of Gastric Cancer from Dredging Triple Energizer[J].Western Journal of Traditional Chinese Medicine,2021,34(09):58.[doi:10.12174/j.issn.2096-9600.2021.07.14]
[4]李晶,王捷虹.半夏泻心汤加减对幽门螺旋杆菌相关性萎缩性胃炎患者胃泌素、胃蛋白酶的影响[J].西部中医药,2023,36(09):5.[doi:10.12174/j.issn.2096-9600.2023.09.02]
 LI Jing,WANG Jiehong.Effects of Modified Banxia Xiexin Tang on Gastrin and Pepsin in Patients with Helicobacter pylori Associated Atrophic Gastritis[J].Western Journal of Traditional Chinese Medicine,2023,36(09):5.[doi:10.12174/j.issn.2096-9600.2023.09.02]
[5]张慧,姜璐,陈俊生,等.国医大师李佃贵基于“浊毒”理论辨治慢性萎缩性胃炎癌前病变胃黏膜屏障功能障碍[J].西部中医药,2024,37(08):47.[doi:10.12174/j.issn.2096-9600.2024.08.12]
 ZHANG Hui,JIANG Lu,CHEN Junsheng,et al.National Master of TCM Li Diangui′s Experience in Differentiating and Treating Gastric Mucosal Barrier of Precancerous Lesions in Chronic Atrophic Gastritis Based on "Turbidity-toxin" Theory[J].Western Journal of Traditional Chinese Medicine,2024,37(09):47.[doi:10.12174/j.issn.2096-9600.2024.08.12]

备注/Memo

备注/Memo:
李盟(2000—),女,在读硕士研究生。研究方向:肿瘤疾病的基础与临床研究。陕西省科技厅科研项目(2022JM-465);陕西省中医药管理局中医药科研课题(JCPT004);陕西中医药大学校级科研课题(2016QN07);咸阳市科技局科研课题(2018KT-42)。
更新日期/Last Update: 2024-09-15